腎細胞癌(MK-6482-011)の治療のためのレンバチニブ対カボザンチニブと組み合わせたベルズチファン(MK-6482)の研究
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Dublin、アイルランド、D24NR0A
- Tallaght University Hospital ( Site 3200)
-
Dublin、アイルランド、D07 R2WY
- Mater Misericordiae University Hospital ( Site 3201)
-
Dublin、アイルランド、D07 R2WY
- Mater Private Hospital - Dublin ( Site 3202)
-
-
-
-
Arizona
-
Chandler、Arizona、アメリカ、85224
- Ironwood Cancer & Research Centers ( Site 0077)
-
-
California
-
Los Angeles、California、アメリカ、90048
- Cedars Sinai Medical Center ( Site 0027)
-
Los Angeles、California、アメリカ、90404
- UCLA Hematology/Oncology - Santa Monica ( Site 0048)
-
Orange、California、アメリカ、92868
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095)
-
Orange、California、アメリカ、92868
- University of California, Irvine ( Site 0029)
-
Santa Monica、California、アメリカ、90404
- Providence Saint John's Health Center ( Site 0083)
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20007
- Georgetown University Medical Center ( Site 0006)
-
-
Florida
-
Orlando、Florida、アメリカ、32806
- Orlando Health, Inc. ( Site 0035)
-
Orlando、Florida、アメリカ、32804
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003)
-
-
Georgia
-
Athens、Georgia、アメリカ、30607
- University Cancer & Blood Center, LLC ( Site 0057)
-
Atlanta、Georgia、アメリカ、30322
- Emory University Hospital ( Site 0012)
-
-
Illinois
-
Chicago、Illinois、アメリカ、60607
- Rush University Medical Center ( Site 0040)
-
Peoria、Illinois、アメリカ、61615
- Illinois Cancer Care, PC ( Site 0008)
-
-
Indiana
-
Fort Wayne、Indiana、アメリカ、46845
- Parkview Cancer Institute ( Site 0088)
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40207
- Norton Cancer Institute - St. Matthews ( Site 0065)
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- Tulane University School of Medicine ( Site 0098)
-
-
Massachusetts
-
Burlington、Massachusetts、アメリカ、01805
- Lahey Hospital & Medical Center ( Site 0090)
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49503
- Cancer & Hematology Centers of Western Michigan ( Site 0018)
-
-
Minnesota
-
Saint Louis Park、Minnesota、アメリカ、55426
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005)
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39213
- University of Mississippi Medical Ctr ( Site 0037)
-
-
Nebraska
-
Lincoln、Nebraska、アメリカ、68516
- Cancer Partners of Nebraska ( Site 0086)
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey ( Site 0078)
-
-
New York
-
Lake Success、New York、アメリカ、11042
- R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013)
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center ( Site 0055)
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Levine Cancer Institute ( Site 0004)
-
Durham、North Carolina、アメリカ、27710
- Duke Cancer Institute ( Site 0096)
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- Lehigh Valley Hospital- Cedar Crest-Oncology Clinical Trials ( Site 0056)
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- University of Texas, Southwestern Medical Center ( Site 0015)
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 7001)
-
-
Vermont
-
Burlington、Vermont、アメリカ、05401
- University of Vermont Medical Center ( Site 0001)
-
-
Virginia
-
Roanoke、Virginia、アメリカ、24014
- Blue Ridge Cancer Care - Roanoke ( Site 0043)
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 0093)
-
Wenatchee、Washington、アメリカ、98801
- Central Washington Health Services Association d/b/a Confluence Health ( Site 0061)
-
-
-
-
Buenos Aires
-
CABA、Buenos Aires、アルゼンチン、C1120AAT
- Centro de Urología (CDU) ( Site 0803)
-
Ciudad Autónoma de Buenos Aires、Buenos Aires、アルゼンチン、C1280AEB
- Hospital Británico de Buenos Aires-Oncology ( Site 0801)
-
Ciudad Autónoma de Buenos Aires、Buenos Aires、アルゼンチン、C1426ANZ
- Instituto Alexander Fleming ( Site 0800)
-
-
Buenos Aires F.D.
-
Buenos Aires、Buenos Aires F.D.、アルゼンチン、C1419AHN
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 0804)
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、2000
- Sanatorio Británico-Clinical Oncology Department ( Site 0802)
-
Rosario、Santa Fe Province、アルゼンチン、S2000DSV
- Sanatorio Parque ( Site 0806)
-
-
-
-
Aberdeen City
-
Aberdeen、Aberdeen City、イギリス、AB25 2ZN
- Aberdeen Royal Infirmary-Department of Oncology ( Site 3105)
-
-
Bath And North East Somerset
-
Bath、Bath And North East Somerset、イギリス、BA1 3NG
- Royal United Hospital Bath England ( Site 3108)
-
-
England
-
Nottingham、England、イギリス、NG5 1PF
- Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 3106)
-
-
Essex
-
Southend、Essex、イギリス、SS0 0RY
- Southend University Hospital ( Site 3112)
-
-
London, City of
-
London、London, City of、イギリス、W6 8RF
- Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 3107)
-
Northwood、London, City of、イギリス、HA6 2RN
- Mount Vernon Cancer Centre ( Site 3101)
-
-
Somerset
-
Taunton、Somerset、イギリス、TA1 5DA
- Musgrove Park Hospital ( Site 3103)
-
-
Wales
-
Swansea、Wales、イギリス、SA2 8QA
- Singleton Hospital ( Site 3111)
-
-
-
-
-
Arezzo、イタリア、52100
- Medical Oncology Ospedale San Donato ( Site 1404)
-
Bari、イタリア、70124
- Azienda Ospedaliera Policlinico di Bari ( Site 1402)
-
Milan、イタリア、20132
- IRCCS Ospedale San Raffaele ( Site 1409)
-
Milan、イタリア、20133
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1400)
-
Pavia、イタリア、27100
- Istituti Clinici Scientifici Maugeri Spa ( Site 1403)
-
Roma、イタリア、00168
- Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1410)
-
Terni、イタリア、05100
- Azienda Ospedaliera S. Maria di Terni ( Site 1401)
-
Verona、イタリア、37126
- Ospedale Maggiore Borgo Trento ( Site 1408)
-
-
Forli-Cesena
-
Meldola、Forli-Cesena、イタリア、47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1407)
-
-
Milano
-
Rozzano、Milano、イタリア、20089
- Istituto Clinico Humanitas Research Hospital ( Site 1406)
-
-
Torino
-
Orbassano、Torino、イタリア、10043
- Ospedale San Luigi Gonzaga ( Site 1405)
-
-
-
-
-
Utrecht、オランダ、3584 CX
- Universitair Medisch Centrum Utrecht ( Site 1910)
-
-
Limburg
-
Sittard-Geleen、Limburg、オランダ、6162 BG
- Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1904)
-
-
North Brabant
-
Breda、North Brabant、オランダ、4818 CK
- Amphia Hospital Location Molengracht ( Site 1912)
-
-
North Holland
-
Amsterdam、North Holland、オランダ、1066 CX
- Antoni van Leeuwenhoek Ziekenhuis ( Site 1901)
-
-
Provincie Friesland
-
Leeuwarden、Provincie Friesland、オランダ、8934 AD
- Medisch Centrum Leeuwarden ( Site 1905)
-
-
South Holland
-
Rotterdam、South Holland、オランダ、3015 GD
- Erasmus MC ( Site 1913)
-
Schiedam、South Holland、オランダ、3118 JH
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1909)
-
The Hague、South Holland、オランダ、2545 AA
- Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1917)
-
-
-
-
New South Wales
-
St Leonards、New South Wales、オーストラリア、2065
- GenesisCare North Shore ( Site 4011)
-
-
South Australia
-
Elizabeth Vale、South Australia、オーストラリア、5112
- Lyell McEwin Hospital ( Site 4004)
-
-
Victoria
-
Frankston、Victoria、オーストラリア、3199
- Peninsula Health Frankston Hospital ( Site 4001)
-
Melbourne、Victoria、オーストラリア、3000
- Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 4010)
-
-
-
-
-
Vienna、オーストリア、1020
- Krankenhaus der Barmherzigen Brüder Wien ( Site 1041)
-
Vienna、オーストリア、1090
- Medizinische Universität Wien ( Site 1021)
-
-
State of Vienna
-
Vienna、State of Vienna、オーストリア、1160
- Klinik Ottakring-1.Medizinische Abteilung - Zentrum für Onkologie und Hämatologie ( Site 1031)
-
-
Styria
-
Graz、Styria、オーストリア、8036
- Medizinische Universitätsklinik Graz ( Site 1051)
-
-
Upper Austria
-
Linz、Upper Austria、オーストリア、4020
- Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 1001)
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre ( Site 0109)
-
Edmonton、Alberta、カナダ、T6G 1Z2
- Cross Cancer Institute ( Site 0111)
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- BC Cancer Vancouver-Clinical Trials Unit ( Site 0110)
-
-
New Brunswick
-
Moncton、New Brunswick、カナダ、E1C 6Z8
- The Moncton Hospital ( Site 0101)
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8V 5C2
- Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0114)
-
Kingston、Ontario、カナダ、K7L 2V7
- Kingston Health Sciences Centre ( Site 0105)
-
Ottawa、Ontario、カナダ、K1H 8L6
- The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0116)
-
Toronto、Ontario、カナダ、M4N 3M5
- Sunnybrook Health Sciences - Odette Cancer Centre ( Site 0113)
-
-
Quebec
-
Greenfield Park、Quebec、カナダ、J4V 2H1
- CISSS de la Monteregie-Centre ( Site 0103)
-
Québec、Quebec、カナダ、G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0115)
-
Sherbrooke、Quebec、カナダ、J1H 5N4
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0102)
-
-
-
-
-
Thessaloniki、ギリシャ、570 01
- European Interbalkan Medical Center-Oncology Department ( Site 3300)
-
-
Achaia
-
Pátrai、Achaia、ギリシャ、26504
- UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 3302)
-
-
Attica
-
Athens、Attica、ギリシャ、115 28
- Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 3304)
-
Athens、Attica、ギリシャ、151 25
- Athens Medical Center ( Site 3303)
-
Chaïdári、Attica、ギリシャ、124 62
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 3301)
-
-
-
-
Antioquia
-
Medellín、Antioquia、コロンビア、050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 0505)
-
-
Cesar Department
-
Valledupar、Cesar Department、コロンビア、200001
- Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 0508)
-
-
Cundinamarca
-
Bogotá、Cundinamarca、コロンビア、111511
- Instituto Nacional de Cancerología-Clinical Oncology ( Site 0500)
-
-
Santander Department
-
Piedecuesta、Santander Department、コロンビア、681017
- Fundación Cardiovascular de Colombia ( Site 0501)
-
-
-
-
Canton Ticino
-
Bellinzona、Canton Ticino、スイス、6500
- Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 1604)
-
-
Canton of Geneva
-
Geneva、Canton of Geneva、スイス、1211
- Hopitaux Universitaires de Geneve HUG ( Site 1602)
-
-
Canton of Zurich
-
Zurich、Canton of Zurich、スイス、8001
- Universitaetsspital Zuerich ( Site 1601)
-
-
Kanton Graubünden
-
Chur、Kanton Graubünden、スイス、7000
- Kantonsspital Graubuenden ( Site 1600)
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1507)
-
Barcelona、スペイン、08036
- Hospital Clinic i Provincial ( Site 1500)
-
Barcelona、スペイン、08041
- Hospital Santa Creu i Sant Pau ( Site 1501)
-
Madrid、スペイン、28009
- Hospital General Universitario Gregorio Maranon ( Site 1505)
-
Madrid、スペイン、28040
- Hospital Clinico San Carlos... ( Site 1504)
-
Seville、スペイン、41013
- Hospital Virgen del Rocio ( Site 1503)
-
-
La Coruna
-
A Coruña、La Coruna、スペイン、15006
- Complejo Hospitalario Universitario A Coruna ( Site 1502)
-
-
Madrid, Comunidad de
-
Madrid、Madrid, Comunidad de、スペイン、28041
- Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1508)
-
-
-
-
-
Hradec Králové、チェコ、500 05
- Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 2201)
-
-
Brno-mesto
-
Brno、Brno-mesto、チェコ、656 53
- Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 2203)
-
-
Praha 4
-
Prague、Praha 4、チェコ、140 59
- Fakultni Thomayerova nemocnice-Onkologicka klinika 1. LF UK ( Site 2200)
-
-
Praha 5
-
Prague、Praha 5、チェコ、150 06
- Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 2205)
-
-
South Bohemian Region
-
České Budějovice、South Bohemian Region、チェコ、37001
- Nemocnice Ceske Budejovice-Onkologicke oddeleni ( Site 2204)
-
-
-
-
Araucania
-
Temuco、Araucania、チリ、4800827
- James Lind Centro de Investigacion del Cancer ( Site 0402)
-
-
Region M. de Santiago
-
Santiago、Region M. de Santiago、チリ、8420383
- Bradfordhill-Clinical Area ( Site 0400)
-
-
-
-
-
Berlin、ドイツ、10117
- Charite Universitaetsmedizin Berlin ( Site 1321)
-
Berlin、ドイツ、13125
- HELIOS Klinikum Berlin-Buch ( Site 1311)
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau、Baden-Wurttemberg、ドイツ、79106
- Klinik fuer Urologie ( Site 1303)
-
Heidelberg、Baden-Wurttemberg、ドイツ、69120
- NCT-Department of Medical Oncology ( Site 1320)
-
-
Bavaria
-
Nuremberg、Bavaria、ドイツ、90419
- Klinikum Nuernberg Nord ( Site 1300)
-
-
Hesse
-
Frankfurt am Main、Hesse、ドイツ、60590
- Universitaetsklinikum Frankfurt ( Site 1301)
-
-
North Rhine-Westphalia
-
Aachen、North Rhine-Westphalia、ドイツ、52074
- Universitaetsklinikum Aachen AOER ( Site 1317)
-
-
Saarland
-
Homburg/ Saar、Saarland、ドイツ、66421
- Universitaetsklinikum des Saarlandes ( Site 1305)
-
-
Saxony-Anhalt
-
Halle、Saxony-Anhalt、ドイツ、06120
- Krankenhaus Martha Maria Halle-Doelau ( Site 1314)
-
-
Thuringia
-
Erfurt、Thuringia、ドイツ、99089
- Helios Klinikum Erfurt GmbH ( Site 1315)
-
-
-
-
Pirkanmaa
-
Tampere、Pirkanmaa、フィンランド、33520
- Tampereen yliopistollinen sairaala ( Site 1801)
-
-
Southwest Finland
-
Turku、Southwest Finland、フィンランド、20520
- TYKS ( Site 1802)
-
-
Uusimaa
-
Helsinki、Uusimaa、フィンランド、00290
- HYKS ( Site 1800)
-
-
-
-
-
Paris、フランス、75020
- Hopital Tenon ( Site 1213)
-
-
Ain
-
Reims、Ain、フランス、51726
- Institut Jean Godinot ( Site 1216)
-
-
Alpes-Maritimes
-
Nice、Alpes-Maritimes、フランス、06189
- Centre Antoine Lacassagne ( Site 1217)
-
-
Bas-Rhin
-
Strasbourg、Bas-Rhin、フランス、67200
- Hopitaux Universitaires de Strasbourg- Hopital de Hautepierre ( Site 1218)
-
-
Gironde
-
Bordeaux、Gironde、フランス、33000
- CHU de Bordeaux- Hopital Saint Andre ( Site 1209)
-
-
Haute-Garonne
-
Toulouse、Haute-Garonne、フランス、31059
- Institut Claudius Regaud ( Site 1215)
-
-
Haute-Vienne
-
Limoges、Haute-Vienne、フランス、87039
- Clinique Francois Chenieux ( Site 1210)
-
-
Loire-Atlantique
-
Saint-Herblain、Loire-Atlantique、フランス、44805
- Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 1201)
-
-
Maine-et-Loire
-
Angers、Maine-et-Loire、フランス、49055
- Institut de Cancerologie de l Ouest Site Paul Papin ( Site 1200)
-
-
-
-
-
São Paulo、ブラジル、01321-001
- BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0311)
-
São Paulo、ブラジル、01321-001
- Hospital Paulistano - Amil Clinical Research ( Site 0308)
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、ブラジル、59151600
- Liga Norte Riograndense Contra o Cancer ( Site 0313)
-
-
Rio Grande do Sul
-
Porto Alegre、Rio Grande do Sul、ブラジル、90110-270
- Centro Gaucho Integrado de Oncologia ( Site 0304)
-
-
-
-
-
Liège、ベルギー、4000
- CHU de Liege ( Site 1102)
-
-
Bruxelles-Capitale, Region de
-
Anderlecht、Bruxelles-Capitale, Region de、ベルギー、1070
- Institut Jules Bordet ( Site 1103)
-
Brussels、Bruxelles-Capitale, Region de、ベルギー、1200
- Cliniques Universitaires Saint Luc - Bruxelles ( Site 1105)
-
-
Hainaut
-
Gilly、Hainaut、ベルギー、6060
- Grand Hopital de Charleroi ( Site 1104)
-
-
Oost-Vlaanderen
-
Ghent、Oost-Vlaanderen、ベルギー、9000
- UZ Gent ( Site 1100)
-
-
Vlaams-Brabant
-
Leuven、Vlaams-Brabant、ベルギー、3000
- UZ Leuven ( Site 1101)
-
-
-
-
Greater Poland Voivodeship
-
Poznan、Greater Poland Voivodeship、ポーランド、60-569
- Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2401)
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz、Kuyavian-Pomeranian Voivodeship、ポーランド、85-796
- Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2402)
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、ポーランド、31-115
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - O-Klinika Onkologii Klinicznej ( Site 2403)
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、ポーランド、02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2400)
-
-
-
-
Cluj
-
Cluj-Napoca、Cluj、ルーマニア、400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2500)
-
Cluj-Napoca、Cluj、ルーマニア、400015
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2501)
-
-
Dolj
-
Craiova、Dolj、ルーマニア、200542
- Centrul de Oncologie "Sfântul Nectarie" ( Site 2502)
-
-
-
-
Ivanovo Oblast
-
Ivanovo、Ivanovo Oblast、ロシア、153040
- Ivanovo Regional Oncology Dispensary ( Site 2616)
-
-
Moscow
-
Moscow、Moscow、ロシア、119285
- FSBI United Hospital with Polyclinic ( Site 2613)
-
Moscow、Moscow、ロシア、125130
- SHI of Moscow City Oncology Clinical Hospital - 62 ( Site 2614)
-
-
Moscow Oblast
-
Krasnogorsk、Moscow Oblast、ロシア、143442
- MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 2618)
-
Moscow、Moscow Oblast、ロシア、121205
- Hadassah Medical-Oncology department ( Site 2609)
-
-
Volgograd Oblast
-
Volzhsky、Volgograd Oblast、ロシア、404120
- Volgograd Regional Uronephrological Center ( Site 2615)
-
-
Yaroslavl Oblast
-
Yaroslavl、Yaroslavl Oblast、ロシア、150054
- Yaroslavl Regional Cancer Hospital-Oncology ( Site 2619)
-
-
-
-
-
Fukuoka、日本、812-8582
- Kyushu University Hospital ( Site 5005)
-
Niigata、日本、951-8520
- Niigata University Medical & Dental Hospital ( Site 5013)
-
Osaka、日本、541-8567
- Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 5016)
-
Tokyo、日本、113-8603
- Nippon Medical School Hospital ( Site 5006)
-
Tokyo、日本、123-8558
- Tokyo Women's Medical University Adachi Medical Center ( Site 5015)
-
Tokyo、日本、160-8582
- Keio University Hospital ( Site 5011)
-
-
Aichi-ken
-
Toyoake、Aichi-ken、日本、470-1192
- Fujita Health University Hospital ( Site 5003)
-
-
Chiba
-
Kashiwa、Chiba、日本、2778577
- National Cancer Center Hospital East ( Site 5000)
-
Sakura、Chiba、日本、285-8741
- Toho University Sakura Medical Center ( Site 5014)
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、060-8543
- Sapporo Medical University Hospital ( Site 5008)
-
-
Hyōgo
-
Kobe、Hyōgo、日本、650-0047
- Kobe City Medical Center General Hospital ( Site 5017)
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、236-0004
- Yokohama City University Hospital ( Site 5007)
-
-
Nara
-
Kashihara、Nara、日本、634-0813
- Nara Medical University Hospital ( Site 5002)
-
-
Osaka
-
Sakai、Osaka、日本、590-0197
- Kindai University Hospital ( Site 5010)
-
Suita、Osaka、日本、565-0871
- The University of Osaka Hospital ( Site 5012)
-
-
Shizuoka
-
Hamamatsu、Shizuoka、日本、431-3192
- Hamamatsu University Hospital ( Site 5004)
-
-
Tokyo
-
Bunkyo-ku、Tokyo、日本、113-8510
- Institute of Science Tokyo Hospital ( Site 5009)
-
Minato-ku、Tokyo、日本、105-8470
- Toranomon Hospital ( Site 5001)
-
-
-
-
-
Seoul、韓国、05505
- Asan Medical Center ( Site 4200)
-
Seoul、韓国、06351
- Samsung Medical Center ( Site 4201)
-
-
Jeonranamdo
-
Hwasun、Jeonranamdo、韓国、58128
- Chonnam National University Hwasun Hospital-Oncology ( Site 4203)
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC)
- Disease progression on or after an anti-programmed cell death-1/ligand 1 (PD-1/L1) therapy as either first or second-line treatment for locally advanced/metastatic RCC or as adjuvant treatment or neoadjuvant/adjuvant with progression on or within 6 months of last dose
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria as assessed by local study investigator
- Karnofsky performance status (KPS) score of at least 70% assessed within 10 days before randomization
- Received no more than 2 prior systemic regimens including: one anti-PD-1/L1 containing adjuvant or neoadjuvant/adjuvant regimens with progression on or within 6 months from the last dose of that regimen OR one or 2 regimens for locoregional/advanced disease
- Received only 1 prior antiPD-1/L1 therapy for adjuvant, neoadjuvant/adjuvant or locally advanced/metastatic RCC
- A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of belzutifan or lenvatinib in the belzutifan+lenvatinib arm, whichever occurs last, and 23 days after the last dose of cabozantinib
- A female participant is eligible to participate if they are not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) or a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention in the belzutifan+ lenvatinib arm, or 120 days after the last dose of study intervention in the cabozantinib arm
- Adequately controlled blood pressure
- Adequate organ function
Exclusion Criteria:
- A pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or requires chronic supplemental oxygen
- Known additional malignancy that is progressing or has required active treatment within the past 3 years except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
- Known central nervous system (CNS) metastases and/or carcinomatous meningitis
- Clinically significant cardiac disease within 6 months of first dose of study intervention
- Prolongation of corrected QT interval (QTc) interval to >480 ms.
- Symptomatic pleural effusion (e.g.,cough, dyspnea, pleuritic chest pain) that is not clinically stable
- Pre-existing ≥Grade 3 gastrointestinal or nongastrointestinal fistula.
- Moderate to severe hepatic impairment
- History of significant bleeding within 3 months before randomization.
- History of solid organ transplantation
- Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
- Unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption)
- Known hypersensitivity or allergy to the active pharmaceutical ingredients or any component of the study intervention formulations
- Received colony-stimulating factors [eg, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GMCSF) or recombinant erythropoietin (EPO)] within 28 days before randomization
- Prior treatment with belzutifan or another hypoxia-inducible factor (HIF)-2α inhibitor
- Prior treatment with lenvatinib
- Prior treatment with cabozantinib
- Currently participating in a study of an investigational agent or using an investigational device
- Active infection requiring systemic therapy
- History of human immunodeficiency virus (HIV) infection
- History of hepatitis B or known active hepatitis C infection
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Belzutifan + Lenvatinib
Participants received daily oral dose of belzutifan 120 mg and lenvatinib 20 mg until progressive disease or discontinuation. |
Oral administration
他の名前:
Oral administration
他の名前:
|
|
アクティブコンパレータ:Cabozantinib
Participants received daily oral dose of cabozantinib 60 mg until progressive disease or discontinuation. |
Oral administration
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
時間枠:Up to approximately 34 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review will be presented. |
Up to approximately 34 months
|
|
Overall Survival (OS)
時間枠:Up to approximately 44 months
|
OS is defined as time from randomization to death due to any cause. |
Up to approximately 44 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
時間枠:Up to approximately 24 months
|
ORR is defined as the percentage of participants who have a complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented. |
Up to approximately 24 months
|
|
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
時間枠:Up to approximately 44 months
|
For participants who demonstrate a confirmed complete response (CR: Disappearance of all target lesions) or confirmed partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death. The DOR as assessed by blinded independent central review will be presented. |
Up to approximately 44 months
|
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
時間枠:Up to approximately 44 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 44 months
|
|
Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
時間枠:Up to approximately 44 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 44 months
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
一般刊行物
- Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, Perini R, Zhang Y, Heng DY. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113-121. doi: 10.2217/fon-2022-0802. Epub 2023 Feb 8.
- Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M; LITESPARK-011 Investigators. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet. 2026 Aug 12:S0140-6736(26)01089-5. doi: 10.1016/S0140-6736(26)01089-5. Online ahead of print.
- Heng DYC, Schmidinger M, McDermott R, Park SH, Burotto M, Ciccarese C, Verzoni E, Suarez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, de Velasco G, Valderrama BP, Azad AA, De Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JB, Lin J, Perini RF, Vickery D, Motzer RJ; LITESPARK-011 Investigators. Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy. Ann Oncol. 2026 Oct 25:S0923-7534(26)06893-6. doi: 10.1016/j.annonc.2026.10.109. Online ahead of print.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 6482-011
- MK-6482-011 (その他の識別子:MSD)
- jRCT2031210311 (その他の識別子:jRCT(Japan Registry of Clinical Trials))
- 2020-002075-35 (EudraCT番号)
- U1111-1302-2815 (レジストリ識別子:UTN)
- 2024-510620-39-00 (レジストリ識別子:EU CT)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。